BIOREXIS
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
BIOREXIS
Industry:
Health Care Insurance Therapeutics
Founded:
2001-08-01
Address:
United, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
38 M USD
Current Advisors List
Founder
Investors List
Prism Venture Management
Prism Venture Management investment in Series B - BioRexis
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series B - BioRexis
Anthem Capital Management
Anthem Capital Management investment in Series B - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series B - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series B - BioRexis
Gund Investment, LLC
Gund Investment, LLC investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series A - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series A - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series A - BioRexis
More informations about "BioRexis"
BioRexis - Crunchbase Company Profile & Funding
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to …See details»
Organization | Biorexis
Biorexis Report issue For profit Founded: King of Prussia PA United States (2002)See details»
BioRexis Pharmaceutical Corp. - Drug pipelines, Patents, Clinical ...
Explore BioRexis Pharmaceutical Corp. with its drug pipeline, therapeutic area, technology platform, 1 literature.See details»
BioRexis - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioRexis with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
BioRexis - Contacts, Employees, Board Members, Advisors & Alumni
Organization. BioRexis . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Number of Board Member and Advisor …See details»
Pfizer to Acquire BioRexis to Access Novel Technology Platform …
Feb 5, 2007 BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with substantially longer duration of …See details»
BioRexis Pharmaceutical Corporation - VentureRadar
BioRexis Pharmaceutical Corporation VentureRadar profile. Find out more about BioRexis Pharmaceutical Corporation including the VentureRadar Innovation and Growth scores, …See details»
Biorexis - Company Profile - Tracxn
Nov 21, 2024 Biorexis ranks 63rd among 217 active competitors. 81 of its competitors are funded while 43 have exited. Overall, Biorexis and its competitors have raised over $7.24B in …See details»
BioRexis - Funding, Financials, Valuation & Investors - Crunchbase
Oncology Therapeutics Network provides integrated solutions primarily related to healthcare and insurance.See details»
BIOREXIS PHARMACEUTICAL CORPORATION | SBIR.gov
DESCRIPTION (provided by investigator): Rexis plans to develop a broad acting antitoxin to Clostridium botulinum Neurotoxin Serotypes A, B and E (possibly C, D, F and G) offering high …See details»
Pfizer to Buy BioRexis
Feb 1, 2007 Pfizer reports that it plans to acquire BioRexis Pharmaceutical, a privately-held biopharmaceutical company with a number of diabetes candidates and a novel technology …See details»
BioRexis Pharmaceutical - PitchBook
BioRexis Pharmaceutical was acquired on 01-Feb-2007. Who acquired BioRexis Pharmaceutical? BioRexis Pharmaceutical was acquired by Pfizer. Data Transparency. Meet our data hygiene …See details»
Pfizer goes shopping and buys diabetes specialists BioRexis
Feb 2, 2007 By buying BioRexis, Pfizer is getting access to “a number of diabetes candidates” plus a novel technology platform for developing new protein drug candidates and David …See details»
Entrepreneur-Turned-Venture Capitalist David King to… - Science …
Sep 14, 2010 Before being acquired by Pfizer in 2007, BioRexis raised $38 million from several venture funds. Now a venture partner with Quaker BioVentures, King, is on the other side of …See details»
BioRexis - Crunchbase
Oncology Therapeutics Network provides integrated solutions primarily related to healthcare and insurance.See details»
Pfizer To Acquire BioRexis To Access Novel Technology Platform …
Acquisition is a Further Step in Pfizer Strategy to Accelerate Business Development and Licensing Activity. New York - Pfizer Inc announced that it has entered into an agreement to …See details»
Research programme: GLP-1 fusion peptide - BioRexis
BioRexis Pharmaceutical Corporation is developing GLP-1 fusion peptide [GLP-1-Tf, BRX0585] for the treatment of type 2 diabetes.BioRexis' proprietary Engineered ... If your organization …See details»
Respironics - Crunchbase Company Profile & Funding
BioRexis is a biopharmaceutical company. It develops and produces biopharmaceuticals. BioRexis offers protein and peptide drugs with pharmacology and trans-bodies to replace …See details»
Biolexis
Dr. David J. Bearss is a trendsetting entrepreneur of drug development with over 20 years’ of experience. Not only is David an industry-leading expert in small molecule drug development …See details»
BioRexis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
BioRexis is actively using 11 technologies for its website, according to BuiltWith. These include SPF , IPv6 , and Cloudflare Hosting . Website Tech Stack by BuiltWithSee details»